Australia markets closed

Vaccitech plc (VACC)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
2.3450+0.0350 (+1.52%)
At close: 03:59PM EST
2.2000 -0.14 (-6.18%)
After hours: 04:15PM EST
Full screen
Trade prices are not sourced from all markets
Previous close2.3100
Open2.2500
Bid2.2000 x 3200
Ask2.3800 x 1200
Day's range2.1917 - 2.3800
52-week range2.0800 - 12.7100
Volume27,420
Avg. volume38,300
Market cap87.46M
Beta (5Y monthly)N/A
PE ratio (TTM)7.82
EPS (TTM)0.3000
Earnings date10 Nov 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est18.75
  • GlobeNewswire

    Vaccitech to Host KOL Webinar on the SNAPvax™ Platform for Inducing Tolerance to Treat Celiac and other Autoimmune Diseases

    OXFORD, United Kingdom, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced that it will host a Key Opinion Leader (KOL) webinar on its SNAPvax™ Platform and application in tolerogenic immunotherapies for celiac disease and other autoimmune diseases on Monday, November 28, 2022 at 4:30 pm ET. Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infec

  • Simply Wall St.

    Vaccitech Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag

    Vaccitech ( NASDAQ:VACC ) Third Quarter 2022 Results Key Financial Results Revenue: US$6.17m (up by US$6.15m from 3Q...

  • GlobeNewswire

    Vaccitech Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

    OXFORD, United Kingdom, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the third quarter ended September 30, 2022 and provided an overview of the Company’s recent corporate developments. Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, autoimmunity, and cancer. “This has been a very exciting qua